[
  {
    "ts": null,
    "headline": "Dividend Income: Bert's September Dividend Income Summary",
    "summary": "In May, we earned $5,140.66 in dividend income. That is a 19% dividend increase compared to last year. Read more here.",
    "url": "https://finnhub.io/api/news?id=f0f347ced2c6d2af79bfc7508fe6ee4d0be5946cc7a9ba1a6763544286f5827e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761499080,
      "headline": "Dividend Income: Bert's September Dividend Income Summary",
      "id": 137213588,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166399130/image_2166399130.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "In May, we earned $5,140.66 in dividend income. That is a 19% dividend increase compared to last year. Read more here.",
      "url": "https://finnhub.io/api/news?id=f0f347ced2c6d2af79bfc7508fe6ee4d0be5946cc7a9ba1a6763544286f5827e"
    }
  },
  {
    "ts": null,
    "headline": "More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now",
    "summary": "Five of the highest-yielding S&P 500 stocks offer incredible, dependable yields from quality blue-chip companies you can buy and hold forever.",
    "url": "https://finnhub.io/api/news?id=896895330c1e6f02ec3df9314f7992ff90df77171db4c2cebae13b9f256cb1db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761488381,
      "headline": "More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now",
      "id": 137216471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Five of the highest-yielding S&P 500 stocks offer incredible, dependable yields from quality blue-chip companies you can buy and hold forever.",
      "url": "https://finnhub.io/api/news?id=896895330c1e6f02ec3df9314f7992ff90df77171db4c2cebae13b9f256cb1db"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study",
    "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced final overall survival results from their Phase 3 EMBARK study. ​The study evaluated XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate […]",
    "url": "https://finnhub.io/api/news?id=d76ff3c4d1deb7b18db15c81b89ae126240cdaad703d39512908c5655cbd71b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761477909,
      "headline": "Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study",
      "id": 137216542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced final overall survival results from their Phase 3 EMBARK study. ​The study evaluated XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate […]",
      "url": "https://finnhub.io/api/news?id=d76ff3c4d1deb7b18db15c81b89ae126240cdaad703d39512908c5655cbd71b3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Is Another Monster Quarter Coming",
    "summary": "Discover why Eli Lillyâs Q3 results and Adverum acquisition boost its risk/reward profile.",
    "url": "https://finnhub.io/api/news?id=7b335fd199e2e11bf7a03b65a5dae893b468b8b610800c92c23b6a88cf3faf8f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761466500,
      "headline": "Eli Lilly: Is Another Monster Quarter Coming",
      "id": 137211818,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202955977/image_1202955977.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Eli Lillyâs Q3 results and Adverum acquisition boost its risk/reward profile.",
      "url": "https://finnhub.io/api/news?id=7b335fd199e2e11bf7a03b65a5dae893b468b8b610800c92c23b6a88cf3faf8f"
    }
  },
  {
    "ts": null,
    "headline": "Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.",
    "summary": "Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).",
    "url": "https://finnhub.io/api/news?id=3ea17542bbe30a846d97b638ab8e19876cadfb13254d95ca591e8d687c0d2e0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761465600,
      "headline": "Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.",
      "id": 137216026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).",
      "url": "https://finnhub.io/api/news?id=3ea17542bbe30a846d97b638ab8e19876cadfb13254d95ca591e8d687c0d2e0f"
    }
  }
]